MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
MetLife, Inc. director William E. Kennard acquired 544 common shares on October 1, 2026, as part of non-management director retainer fees paid in stock; the reported transaction price was $94.35 per share. Kennard elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. His reported direct holdings following the award were 48,248 shares. A separate holding entry lists 10 shares held by the MetLife Policyholder Trust for allocation to eligible policyholders.
MetLife, Inc. estimates variable investment income of at least $600 million pre-tax for the quarter ended September 30, 2026, compared with full-year 2026 guidance of approximately $1.6 billion pre-tax.
The estimate is preliminary and unaudited, and MetLife has not completed its financial closing procedures for the quarter. Actual results could differ materially; the preliminary figures are not a substitute for full financial statements prepared in accordance with U.S. GAAP.
METLIFE INC (MET) has a notice of proposed sale under Rule 144 for common stock held for the account of MetLife Separate Account SPI, identified as an affiliate. The filing lists a proposed sale of 224 shares of common stock through Cantor Fitzgerald & Co. on the NYSE on September 18, 2026.
The notice also reports several small sales of MetLife common stock during the prior three months by MetLife 401(k) plan trusts and various MetLife separate accounts, each involving relatively modest share amounts and dollar values.
METLIFE INC (MET) received a notice under Rule 144 from an affiliate "Separate Account" to sell 45 shares of common stock through Cantor Fitzgerald & Co. on the NYSE, with an indicated market value of $4,380.75, as of September 18, 2026.
The 45 shares to be sold were acquired on December 17, 2019 in a purchase from Bank of America for cash. The notice also lists recent sales of MetLife common stock over the past three months by MetLife-related plans and separate accounts, including various 401(k) and separate account vehicles.
METLIFE INC (MET) filed a notice under Rule 144 for a planned sale of common stock held for the account of Separate Account 149. The notice covers 25 shares of common stock, with an aggregate market value of $2,433.75, to be sold through Cantor Fitzgerald & Co. on or after September 18, 2026 on the NYSE.
METLIFE INC (MET) received a Rule 144 notice covering planned sales of its common stock for the account of the MetLife 401(k) Plan Large Cap Equity Index, managed by an affiliate discretionary manager. The plan intends to sell 266 shares of common stock through Cantor Fitzgerald & Co. on the NYSE, with an indicated aggregate value of $25,895.10. The shares to be sold were acquired by purchase for cash on December 31, 2014 from Goldman Sachs. The notice also lists multiple prior sales of MetLife common stock by related MetLife 401(k) plan trusts and separate accounts during the past three months.
METLIFE INC (MET) reported that Ramy Tadros, President, U.S. Business, acquired 115 shares of common stock on September 8, 2026 through a grant/award transaction. The shares reflect imputed reinvestment of dividends on deferred shares under the MetLife Leadership Deferred Compensation Plan, bringing his directly held common shares to 212,695.
METLIFE INC (MET) reported that director William E. Kennard acquired 294 shares of common stock on September 8, 2026 as a grant related to imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors at a reference value of $95.50 per share. Following this award, he holds 47,704 shares directly and 10 shares indirectly through the MetLife Policyholder Trust.
METLIFE INC (MET) reported that director Christian Stephane Mumenthaler acquired 21 shares of common stock on September 8, 2026 through a grant classified as an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, he holds 3,474 shares directly. No Rule 10b5-1 trading plan is reported.
METLIFE INC (MET) reported that director Laura J. Hay acquired 39 shares of common stock on September 8, 2026 at an imputed price of $95.50 per share. The acquisition reflects imputed reinvestment of dividends on deferred shares under MetLife’s Deferred Compensation Plan for Non-Management Directors, bringing her direct holdings to 6,357 shares.